DRG2 and cancer: The strategic inhibition of multiple factors—DRG2, TRAPPC4, HIP1R, and CMTM6—represents a compelling approach to regulate PD-L1 surface levels on cancer cells, potentially reversing immune resistance mechanisms and amplifying the effectiveness of PD-1/PD-L1 blockade strategies.